New treatment, zanzalintinib, for advanced kidney cancer
A recent clinical trial looked at a new anti-cancer medication [...]
Treatment of translocation kidney cancer
Translocation kidney cancer is a rare type of kidney cancer [...]
Real world treatment of advanced kidney cancer
Nearly 30% of new kidney cancer cases are diagnosed at [...]
ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
Pembrolizumab plus lenvatinib for non-clear cell kidney cancer
Immunotherapy combinations are becoming the standard treatment for people with [...]
Adjuvant therapy for kidney cancer
Adjuvant therapy aims to reduce the risk of the cancer [...]
TKI treatment breaks may not affect outcomes in kidney cancer
The results of the phase 2/3 STAR trial were published [...]
Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Side effect management for kidney cancer treatments
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
Treatment of rare subtypes of kidney cancer
At the International Kidney Cancer Symposium (IKCS) in North America [...]
